Nebennieren-Inzidentalom – Differenzialdiagnose und Management

Raumforderungen der Nebenniere sind ein häufiger Zufallsbefund in der Schnittbildgebung. Dieser Artikel erläutert, welche Diagnostik notwendig ist (und welche nicht), um therapiebedürftige Raumforderungen zu identifizieren, und wie anschließend das weitere Management erfolgt.

Abstract

Adrenal masses are common incidental findings on imaging procedures.

In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but in up to 20 % they require therapeutic intervention. The aim of this article is to provide essential guidance for clinicians regarding clinical management of patients with adrenal incidentalomas based on the respective current clinical guidelines. The following main questions are addressed: How to distinguish a nonfunctioning incidentaloma from a functioning one and how to assess risk of malignancy? How to define and manage low-level autonomous cortisol secretion, formerly called “subclinical” Cushing’s syndrome? Which patients have to be treated surgically and which approach should be used? What follow-up is indicated if the adrenal incidentaloma is not surgically removed?

Schlüsselwörter

Nebennieren-Adenom - Cortisol - Hyperkortisolismus - Phäochromozytom - Nebennieren-Karzinom

Key words

adenoma - cortisol - hypercortisolism - pheochromocytoma - adrenocortical carcinoma

Publication History

Article published online:
31 January 2022

• Literatur

• 1 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34 DOI: 10.1530/EJE-16-0467.
• 2 Sherlock M, Scarsbrook A, Abbas A. et al. Adrenal Incidentaloma. Endocr Rev 2020; 41 DOI: 10.1210/endrev/bnaa008.
• 3 Kebebew E. Adrenal Incidentaloma. N Engl J Med 2021; 384: 1542-1551 DOI: 10.1056/NEJMcp2031112.
• 4 Terzolo M, Stigliano A, Chiodini I. et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164: 851-870 DOI: 10.1530/EJE-10-1147.
• 5 Ebbehoj A, Li D, Kaur RJ. et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8: 894-902 DOI: 10.1016/S2213-8587(20)30314-4.
• 6 Lacroix A, Feelders RA, Stratakis CA. et al. Cushing’s syndrome. Lancet 2015; 386: 913-927 DOI: 10.1016/s0140-6736(14)61375-1.
• 7 Kjellbom A, Lindgren O, Puvaneswaralingam S. et al. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas: A Cohort Study. Ann Intern Med 2021; 174: 1041-1049 DOI: 10.7326/M20-7946.
• 8 Elhassan YS, Alahdab F, Prete A. et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171: 107-116 DOI: 10.7326/M18-3630.
• 9 Asbach E, Reincke M. Diagnostik und Therapie des Conn-Syndroms: neue Aspekte. Dtsch Med Wochenschr 2022; 147
• 10 Cordera F, Grant C, van Heerden J. et al. Androgen-secreting adrenal tumors. Surgery 2003; 134: 874-880 DOI: 10.1016/s0039-6060(03)00410-0.
• 11 Fassnacht M, Assie G, Baudin E. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 1476-1490 DOI: 10.1016/j.annonc.2020.08.2099.
• 12 Lenders JWM, Kerstens MN, Amar L. et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020; 38: 1443-1456 DOI: 10.1097/hjh.0000000000002438.
• 13 Lenders JWM, Duh Q-Y, Eisenhofer G. et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942 DOI: 10.1210/jc.2014-1498.
• 14 Eisenhofer G, Prejbisz A, Peitzsch M. et al. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clin Chem 2018; 64: 1646-1656 DOI: 10.1373/clinchem.2018.291369.
• 15 Eisenhofer G, Lattke P, Herberg M. et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem 2013; 50: 62-69 DOI: 10.1258/acb.2012.012066.
• 16 Eisenhofer G, Goldstein DS, Walther MM. et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656-2666 DOI: 10.1210/jc.2002-030005.
• 17 Funder JW, Carey RM, Fardella C. et al. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281 DOI: 10.1210/jc.2008-0104.
• 18 Dinnes J, Bancos I, Ferrante di Ruffano L. et al. MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175: R51-R64 DOI: 10.1530/EJE-16-0461.
• 19 Bancos I, Taylor AE, Chortis V. et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol 2020; 8: 773-781 DOI: 10.1016/S2213-8587(20)30218-7.
• 20 Lorenz K, Langer P, Niederle B. et al. Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK). Langenbecks Arch Surg 2019; 404: 385-401 DOI: 10.1007/s00423-019-01768-z.